An expanded access record providing MTX-001 (Dermacyte Liquid) in Cutaneous Ulcer, Diabetic Ulcer and Surgical Wound Dehiscence, sponsored by Merakris Therapeutics. Available at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Merakris Therapeutics · Expanded access
Among 152 studies in Pressure Ulcer with a site in United States — 26 open to participants now, 30 under way, none of them phase 3. Pressure Ulcer · United States.
Among the 152 studies in Pressure Ulcer with a site in United States, this one is the only one of another kind, and was the 136th registered.
545 studies on the registry are indexed under Pressure Ulcer; 129 are open to participants now.
Browse Pressure Ulcer studies →26 of the 152 studies in Pressure Ulcer with a site in United States are open now, in 1 country. Each count lists the studies.
Of the 61 Pressure Ulcer studies recruiting now, 45 (74%) set no upper age limit and 6 (10%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →152 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked.
Median enrollment 48 across the 118 interventional studies, 135 across the 33 observational. Of the 93 that completed or were terminated, 38 (41%) have results posted.
72 of 152 have an industry lead sponsor. The 10 most frequent:
Merakris Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Merakris Therapeutics has 1 study filed under Pressure Ulcer — fewer than ten, so there is no comparison to draw.
11 of the studies in Pressure Ulcer with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05496296ULURU Inc.Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries | 2026-12 |
| NCT07158658NuScience Medical Biologics, LLCProspective Case Series Evaluating the Efficacy and Safety of NeoThelium FT for Chronic Pressure Ulcers | 2026-12-01 |
| NCT07653165West Boca Center for Wound HealingUse of Hydroprep Wound Therapy With Motion Negative Pressure Therapy for Treatment of Chronic Lower Extremity Wounds | 2026-12-31 |
| NCT04726306Northwell HealthDiagnostic Precision and Accuracy Using the Teed Scoring System Versus the O'Neill Grading System | 2026-12-31 |
| NCT05458947Wake Forest University Health SciencesPhysical Therapy Wound Care Modalities in Patients With Spinal Cord Injury (SCI) | 2027-01 |
Among the 152 studies in Pressure Ulcer with a site in United States, from their registry updates:
The objective of this study is to make Dermacyte Liquid available on an expanded access basis to treat cutaneous ulcers and wounds refractory to initial treatment or that do not have adequate alternative treatments. Minimal data will be collected to evaluate the efficacy and safety of Dermacyte Liquid.
The primary purpose is to provide expanded access of Dermacyte Liquid to subjects who have serious cutaneous ulcers and wounds (e.g., ulcers related to diabetes mellitus, venous insufficiency, complications of systemic sclerosis or rheumatic disease; decubitus ulcers, burns, acute trauma, wound dehiscence, ischemic ulcers, and mixed etiology ulcers). Eligible subjects must have a high likelihood of significant morbidity, loss of quality of life, potential amputation, or mortality without efficacious treatment. As there are many types of patients who may be enrolled, study results will not have statistical significance.
545 studies on the registry are indexed under Pressure Ulcer; 129 are open to participants now.
Browse Pressure Ulcer studies →Merakris Therapeutics is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Compared within Pressure Ulcer, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Ulcer. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Repeat dose subcutaneous drug injection for the treatment of serious chronic wounds.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
Contact the providerGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merakris Therapeutics